To include your compound in the COVID-19 Resource Center, submit it here.

Opdivo meets in Chinese Phase III for second-line NSCLC

Bristol-Myers Squibb Co. (NYSE:BMY) said the Phase III CheckMate -078 trial of Opdivo nivolumab

Read the full 142 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE